ArticleHelicobacter2019
Helicobacter pylori antimicrobial resistance and antibiotic consumption in the low-resource Central America setting.
Article in Helicobacter, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Gastric cancer burden and regional disparities among Helicobacter pylori-positive patients in the Americas: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- The global prevalence of gastric cancer in Helicobacter pylori-infected individuals: a systematic review and meta-analysis.BMC infectious diseases · 2023Pooled it
- The prevalence of clarithromycin-resistantPeerJ · 2023Pooled it
- Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial.Cancer prevention research (Philadelphia, Pa.) · 2026Trial
- Establishment of a Mesoamerican-Caribbean South-South Research Platform: Challenges in the Meriva (Curcuminoids) Gastric Cancer Chemoprevention Trial.Cancer prevention research (Philadelphia, Pa.) · 2024Trial
- Evaluating Antibiotic Resistance in Urban Rivers and Coral Reefs of Belize: Evidence for Hotspots and a Potential Screening Tool.GeoHealth · 2026Article
- Antimicrobial Resistance Patterns and Determinants ofAntibiotics (Basel, Switzerland) · 2025Article
- A critical review onFrontiers in cellular and infection microbiology · 2025Review
- Molecular tools of antibiotic resistance forFrontiers in gastroenterology (Lausanne, Switzerland) · 2024Review
- Control ofMicrobiology spectrum · 2023Article
- Emergence of amoxicillin resistance and identification of novel mutations of the pbp1A gene in Helicobacter pylori in Vietnam.BMC microbiology · 2022Article
- First Chemical Investigation of Korean Wild Mushroom,Pharmaceuticals (Basel, Switzerland) · 2022Article
- Prevalence of antibiotic resistance ofAmerican journal of translational research · 2022Article
- Antibiotic Resistance of Helicobacter pylori Isolated from Patients after Partial Gastrectomy: A Retrospective Study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021Article
- Prevalence of Helicobacter pylori Antimicrobial Resistance Among Chilean Patients.Archives of medical research · 2021Article
- Impact of previous metronidazole exposure on metronidazole-based second-line quadruple therapy for Helicobacter pylori infection.The Korean journal of internal medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAntimicrobial resistance is a global public health problem, particularly in low- and middle-income countries (LMICs), where antibiotics are often obtained without a prescription. H. pylori antimicrobial resistance patterns are informative for patient care and gastric cancer prevention programs, have been shown to correlate with general antimicrobial consumption, and may guide antimicrobial stewardship programs in LMICs. We report H. pylori resistance and antimicrobial utilization patterns for western Honduras, representative of rural Central America.
methodsIn the context of the western Honduras gastric cancer epidemiology initiative, gastric biopsies from 189 patients were studied for culture and resistance patterns. Antimicrobial utilization was investigated for common H. pylori treatment regimens from regional public (7 antimicrobials) and national private (4 antimicrobials) data, analyzed in accordance with WHO anatomical therapeutic chemical defined daily doses (DDD) method and expressed as DDD/1000 inhabitants per day (DID) and per year (DIY).
resultsH. pylori was successfully cultured from 116 patients (56% males, mean age: 54), and nearly all strains were cagA+ and vacAs1m1+ positive (99% and 90.4%, respectively). Unexpectedly, high resistance was noted for levofloxacin (20.9%) and amoxicillin (10.7%), while metronidazole (67.9%) and clarithromycin (11.2%) were similar to data from Latin America. Significant associations with age, gender, or histology were not noted, with the exception of levofloxacin (28%, P = 0.01) in those with histology limited to non-atrophic gastritis. Total antimicrobial usage in western Honduras of amoxicillin (17.3 DID) and the quinolones had the highest relative utilizations compared with other representative nations.
conclusionsWe observed significant H. pylori resistance to amoxicillin and levofloxacin in the context of high community antimicrobial utilization. This has implications in Central America for H. pylori treatment guidelines as well as antimicrobial stewardship programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.